CN114502592A - 靶向cldn18.2的抗体及其制备方法和应用 - Google Patents
靶向cldn18.2的抗体及其制备方法和应用 Download PDFInfo
- Publication number
- CN114502592A CN114502592A CN202080068747.4A CN202080068747A CN114502592A CN 114502592 A CN114502592 A CN 114502592A CN 202080068747 A CN202080068747 A CN 202080068747A CN 114502592 A CN114502592 A CN 114502592A
- Authority
- CN
- China
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
Description
Claims (24)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910941316.3A CN112707965A (zh) | 2019-09-30 | 2019-09-30 | 靶向cldn18.2的抗体及其制备方法和应用 |
CN2019109413163 | 2019-09-30 | ||
PCT/CN2020/118650 WO2021063336A1 (zh) | 2019-09-30 | 2020-09-29 | 靶向cldn18.2的抗体及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114502592A true CN114502592A (zh) | 2022-05-13 |
Family
ID=75336698
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910941316.3A Pending CN112707965A (zh) | 2019-09-30 | 2019-09-30 | 靶向cldn18.2的抗体及其制备方法和应用 |
CN202080068747.4A Pending CN114502592A (zh) | 2019-09-30 | 2020-09-29 | 靶向cldn18.2的抗体及其制备方法和应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910941316.3A Pending CN112707965A (zh) | 2019-09-30 | 2019-09-30 | 靶向cldn18.2的抗体及其制备方法和应用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220332814A1 (zh) |
EP (1) | EP4039706A4 (zh) |
JP (1) | JP7461469B2 (zh) |
KR (1) | KR20220075396A (zh) |
CN (2) | CN112707965A (zh) |
TW (1) | TWI784322B (zh) |
WO (1) | WO2021063336A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115947851A (zh) * | 2022-12-19 | 2023-04-11 | 华润生物医药有限公司 | 结合cldn18.2的抗体及其用途 |
CN115960229A (zh) * | 2022-09-28 | 2023-04-14 | 华润生物医药有限公司 | 一种cldn18.2抗体及其应用 |
CN115969997A (zh) * | 2022-12-19 | 2023-04-18 | 华润生物医药有限公司 | 一种靶向cldn18.2的抗体药物偶联物及其应用 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113416260B (zh) * | 2021-04-14 | 2022-02-01 | 南京凯地医疗技术有限公司 | 靶向Claudin18.2的特异性嵌合抗原受体细胞及其制备方法和应用 |
WO2022268200A1 (zh) * | 2021-06-25 | 2022-12-29 | 信达生物制药(苏州)有限公司 | 针对密蛋白18.2的抗体及其用途 |
CN115611983A (zh) * | 2021-07-14 | 2023-01-17 | 三优生物医药(上海)有限公司 | Cldn18.2结合分子及其用途 |
WO2023025303A1 (zh) * | 2021-08-26 | 2023-03-02 | 上海君实生物医药科技股份有限公司 | 抗cldn-18.2抗体药物偶联物及其用途 |
CN115991784A (zh) * | 2021-10-19 | 2023-04-21 | 宝船生物医药科技(上海)有限公司 | 抗cd47-cldn18.2双特异性抗体及其用途 |
CN116102649A (zh) * | 2021-11-11 | 2023-05-12 | 上海生物制品研究所有限责任公司 | 抗cldn18.2单克隆抗体及其应用 |
TW202333798A (zh) * | 2021-12-17 | 2023-09-01 | 大陸商信達生物製藥(蘇州)有限公司 | 靶向claudin 18.2的抗體-藥物偶聯物 |
CN114316043B (zh) * | 2021-12-28 | 2022-09-20 | 三优生物医药(上海)有限公司 | 一种TGFβ1抗原结合分子及其应用 |
WO2023231942A1 (zh) * | 2022-05-31 | 2023-12-07 | 石药集团巨石生物制药有限公司 | 重组抗人cldn18.2单克隆抗体-mmae偶联药物的药物组合物 |
CN116082523B (zh) * | 2022-12-30 | 2023-10-13 | 邦恩泰(山东)生物医药科技集团股份有限公司 | 一种靶向Claudin18.2的嵌合抗原受体及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1948693A1 (en) * | 2005-11-24 | 2008-07-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
EP3170842A1 (en) * | 2014-07-17 | 2017-05-24 | Carsgen Therapeutics Limited | Immunologic effector cell of targeted cld18a2, and preparation method and use thereof |
US10421817B1 (en) * | 2019-01-17 | 2019-09-24 | Beijing Mabworks Biotech Co., Ltd. | Antibodies binding human Claudin 18.2 and uses thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
WO2013174404A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
WO2014146672A1 (en) | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
EP3099706B1 (en) * | 2014-01-29 | 2018-10-31 | BioNTech AG | Peptide mimotopes of claudin 18.2 and uses thereof |
WO2016165762A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
US11555070B2 (en) * | 2018-03-08 | 2023-01-17 | Phanes Therapeutics, Inc. | Anti-claudin 18.2 antibodies and uses thereof |
BR112020014591A2 (pt) * | 2018-03-14 | 2020-12-01 | Beijing Xuanyi Pharmasciences Co., Ltd. | anticorpos anticlaudina 18.2 |
-
2019
- 2019-09-30 CN CN201910941316.3A patent/CN112707965A/zh active Pending
-
2020
- 2020-09-29 TW TW109133811A patent/TWI784322B/zh active
- 2020-09-29 US US17/764,338 patent/US20220332814A1/en active Pending
- 2020-09-29 EP EP20872423.7A patent/EP4039706A4/en active Pending
- 2020-09-29 JP JP2022520345A patent/JP7461469B2/ja active Active
- 2020-09-29 KR KR1020227014720A patent/KR20220075396A/ko active Search and Examination
- 2020-09-29 CN CN202080068747.4A patent/CN114502592A/zh active Pending
- 2020-09-29 WO PCT/CN2020/118650 patent/WO2021063336A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1948693A1 (en) * | 2005-11-24 | 2008-07-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
EP3170842A1 (en) * | 2014-07-17 | 2017-05-24 | Carsgen Therapeutics Limited | Immunologic effector cell of targeted cld18a2, and preparation method and use thereof |
US10421817B1 (en) * | 2019-01-17 | 2019-09-24 | Beijing Mabworks Biotech Co., Ltd. | Antibodies binding human Claudin 18.2 and uses thereof |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115960229A (zh) * | 2022-09-28 | 2023-04-14 | 华润生物医药有限公司 | 一种cldn18.2抗体及其应用 |
CN115960229B (zh) * | 2022-09-28 | 2024-02-09 | 华润生物医药有限公司 | 一种cldn18.2抗体及其应用 |
CN115947851A (zh) * | 2022-12-19 | 2023-04-11 | 华润生物医药有限公司 | 结合cldn18.2的抗体及其用途 |
CN115969997A (zh) * | 2022-12-19 | 2023-04-18 | 华润生物医药有限公司 | 一种靶向cldn18.2的抗体药物偶联物及其应用 |
CN115947851B (zh) * | 2022-12-19 | 2024-02-13 | 华润生物医药有限公司 | 结合cldn18.2的抗体及其用途 |
CN115969997B (zh) * | 2022-12-19 | 2024-02-13 | 华润生物医药有限公司 | 一种靶向cldn18.2的抗体药物偶联物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
KR20220075396A (ko) | 2022-06-08 |
EP4039706A4 (en) | 2023-03-01 |
US20220332814A1 (en) | 2022-10-20 |
TWI784322B (zh) | 2022-11-21 |
JP7461469B2 (ja) | 2024-04-03 |
TW202126695A (zh) | 2021-07-16 |
EP4039706A1 (en) | 2022-08-10 |
WO2021063336A1 (zh) | 2021-04-08 |
JP2022550952A (ja) | 2022-12-06 |
CN112707965A (zh) | 2021-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI784322B (zh) | 標靶cldn18.2的抗體及其製備方法和應用 | |
US20210221907A1 (en) | Antibodies specific to trophoblast antigen 2 (trop2) | |
US20210230272A1 (en) | Antibody targeting cldn18.2, bispecific antibody, adc, and car, and applications thereof | |
CN113166246A (zh) | 一种抗体及其用途 | |
CN111196852A (zh) | 抗tigit抗体及其用途 | |
TWI818308B (zh) | 標靶ror1的抗體或其抗原結合片段及製備方法和應用 | |
US20220041748A1 (en) | Antibodies specific to muc18 | |
AU2021337687A1 (en) | Nectin-4 antibodies and uses thereof | |
US20220041749A1 (en) | Antibodies specific to muc18 | |
EP3821006A2 (en) | Antibodies specific to folate receptor alpha | |
WO2021169982A1 (zh) | 靶向EpCAM的抗体及其制备和应用 | |
WO2023016348A1 (en) | Cldn18.2-targeting antibody, bispecific antibody and use thereof | |
WO2023138579A1 (zh) | 抗b7-h7抗体或其抗原结合片段及制备方法和应用 | |
TW202246323A (zh) | 抗claudin—6之抗體及其用途 | |
WO2023052541A1 (en) | Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy | |
CN114685658A (zh) | Ox40的靶向抗体及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40066347 Country of ref document: HK |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: CORR Ref document number: 40066347 Country of ref document: HK Free format text: CORRECTED DATA OF SECTION 20 12.08.2022: (54) CLDN18.2-TARGETING ANTIBODY, PREPARATION METHOD THEREOF, AND USE THEREOF |
|
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 215000 unit 202, A3 / F, 218 Xinghu street, Suzhou Industrial Park, Jiangsu Province Applicant after: Nuona Biological (Suzhou) Co.,Ltd. Address before: 215000 unit 202, A3 / F, 218 Xinghu street, Suzhou Industrial Park, Jiangsu Province Applicant before: Heping Pharmaceutical (Suzhou) Co.,Ltd. |